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Abstract
Background: Dorsal root ganglia (DRG)-neurons are commonly characterized immunocytochemically. Cells are
mostly grouped by the experimenter’s eye as “marker-positive” and “marker-negative” according to their
immunofluorescence intensity. Classification criteria remain largely undefined. Overcoming this shortfall, we
established a quantitative automated microscopy (QuAM) for a defined and multiparametric analysis of adherent
heterogeneous primary neurons on a single cell base.
The growth factors NGF, GDNF and EGF activate the MAP-kinase Erk1/2 via receptor tyrosine kinase signalling. NGF
and GDNF are established factors in regeneration and sensitization of nociceptive neurons. If also the tissue
regenerating growth factor, EGF, influences nociceptors is so far unknown. We asked, if EGF can act on nociceptors,
and if QuAM can elucidate differences between NGF, GDNF and EGF induced Erk1/2 activation kinetics. Finally, we
evaluated, if the investigation of one signalling component allows prediction of the behavioral response to a
reagent not tested on nociceptors such as EGF.
Results: We established a software-based neuron identification, described quantitatively DRG-neuron heterogeneity
and correlated measured sample sizes and corresponding assay sensitivity. Analysing more than 70,000 individual
neurons we defined neuronal subgroups based on differential Erk1/2 activation status in sensory neurons. Baseline
activity levels varied strongly already in untreated neurons. NGF and GDNF subgroup responsiveness correlated
with their subgroup specificity on IB4(+)- and IB4(-)-neurons, respectively. We confirmed expression of EGF-
receptors in all sensory neurons. EGF treatment induced STAT3 translocation into the nucleus. Nevertheless, we
could not detect any EGF induced Erk1/2 phosphorylation. Accordingly, intradermal injection of EGF resulted in a
fundamentally different outcome than NGF/GDNF. EGF did not induce mechanical hyperalgesia, but blocked PGE2-
induced sensitization.
Conclusions: QuAM is a suitable if not necessary tool to analyze activation of endogenous signalling in
heterogeneous cultures. NGF, GDNF and EGF stimulation of DRG-neurons shows differential Erk1/2 activation
responses and a corresponding differential behavioral phenotype. Thus, in addition to expression-markers also
signalling-activity can be taken for functional subgroup differentiation and as predictor of behavioral outcome. The
anti-nociceptive function of EGF is an intriguing result in the context of tissue damage but also for understanding
pain resulting from EGF-receptor block during cancer therapy.
Background
A common denominator of DRG-neurons is their extreme
heterogeneity. They differ in respect to parameters such as
morphology, protein expression and functionality [1]. To
what extent functional differences can be correlated to
expression differences of e.g. ion channels is a matter of
intense research. Mostly the expression of a “marker” is
detected via immunofluorescence microscopy [2]. The
grouping into “marker-positive” and “marker-negative”
cells is commonly performed qualitatively by eye by a
trained experimenter. That a differentiation into a “posi-
tive” and “negative” population can be accomplished by
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addressed. Even further, evaluation through an experimen-
ter’s eye does not allow a definition of exact quantitative
parameters such as which staining intensity qualifies as
“positive”. Thereby comparability between different labs,
experimenters and/or experimental days cannot be ana-
lyzed and has to be questioned. The inherent inaccuracy
of the “by eye” evaluation of intensities might underlie the
wide variety of population sizes reported in the literature.
For example the population size of IB4(+)-neurons ranges
from 40 - 70% [3-5] and population size for TrkA(+)-neu-
rons ranges from 35 - 70% [3,6]). In addition, more com-
plex evaluations such as the gradual increase in activation
of signalling components are near to impossible. This is in
times of highly sophisticated means of quantification
increasingly unsatisfying and problematic. Thus, we set
out to establish a technique to detect and quantify immu-
nofluorescence signals of adherent primary sensory neu-
rons on a single cell base.
Functionality of sensory neurons is mostly addressed
by investigation of ion channel properties and differen-
tial ion channel expression. But the sensitivity of ion
channels can be modulated to a great extend by post
translational modification such as phosphorylation in
the course of intracellular signalling cascade events
[1,7-9]. Therefore activation of a receptor not necessarily
results in the activation of its downstream signalling.
Thus the expression of a receptor cannot be taken as
synonymous with functional changes in these neurons.
To what extent the activation properties of intracellular
signalling cascades themselves can be taken to differenti-
ate functional different neuronal subgroups has not been
addressed so far. Thus we tested if we can detect gra-
dual increase in signalling component activation in sub-
groups of sensory neurons and if investigation of such
cellular signalling kinetics allows to predict if a sub-
stance has a sensitizing effect in behavioral experiments.
Growth factors play a dual role in sensory neurons. In
tissue challenged with potentially damaging stimuli they
mediate neuronal tissue defense and alarm of the organ-
ism. NGF is a potent endogenous stimulator of neuronal
survival and nerve fiber growth [10-12] and is essential
for reinnervation of the skin after injury to cutaneous
nerves [13,14]. But NGF also initiates and maintains
hypersensitivity [15]. Also the growth factor, GDNF,
shows this dual effect. On one hand GDNF is an essen-
tial growth factor for the survival and functional mainte-
nance of a subgroup of nociceptors during development
and after insult [16,17]. On the other hand GDNF has
been reported to contribute to inflammatory hyperalge-
sia in an adjuvant-induced pain model [18] and also
acutely if injected into the skin [19].
On the cellular level, growth factors bind and activate
receptor tyrosine kinase receptors, resulting among
others in the activation of the MAPK Erk1/2 [20,21].
Accordingly, GDNF and NGF-induced mechanical pain
sensitization has been identified to depend on the acti-
vation of Erk1/2 [19,22].
Beyond the known effects of the growth factors NGF
and GDNF on nociceptors, there is another family of
growth factors central to tissue protection and wound
healing, the EGF-family [23]. They are secreted after
tissue injury by platelets, macrophages and fibroblasts
to initiate proliferation and regeneration of the epithe-
lium [24,25]. Wound healing can be improved by EGF
administration [26,27]. Like NGF, EGF exerts its cellu-
lar action via a member of the receptor tyrosine kinase
f a m i l y ,t h eE G F R .T h er e c e p t o r so fN G Fa n dE G F
share many structural features as well as activation
associated intracellular signalling cascades. One signal-
ling component reported in non-nociceptive cells to be
central to EGF-as well as NGF/GDNF signalling is
again Erk1/2 [28].
While described as a survival and growth factor, it is
not known, if EGF has the potential to act on nocicep-
tive neurons. Accordingly, it is also unknown if EGF like
NGF and GDNF sensitizes them. As all three growth
factors act by activation of Erk1/2 this appears likely.
But of special interest is a study in PC12 cells indicating
that the outcome of NGF and EGF treatment can be
very different. While stimulation with NGF leads to
neurite outgrowth and differentiation, stimulation with
EGF leads to the diametral opposing cellular response,
namely cell proliferation [29]. Interestingly, both actions
were described to be mediated by activation of Erk1/2.
How the very same signalling component can result in
two opposing phenotypes has been enigmatic for long.
Only recently the opposing phenotypic outcome of NGF
and EGF signalling was correlated to a differential sti-
mulation kinetic of Erk1/2 phosphorylation induced by
NGF and EGF. While NGF results in a slower but more
pronounced and long-lasting activation, EGF activates
Erk1/2 earlier but only transiently [30]. Thus a cellular
phenotypic outcome can only in part be derived from
the activation of mediating signalling components as
such. Equally important aspects are the kinetic para-
meters like the amplitude, the pace of activation-onset
as well as the duration of activation. Due to the lack of
appropiate techniques it has not been analyzed in noci-
ceptive neurons if there are differences in the kinetics of
Erk1/2 in response to NGF versus EGF.
Therefore‚ we investigated if nociceptive neurons
express the EGF-receptor and if EGF results in activation
of Erk1/2 similar to the growth factors NGF and GDNF.
We thereby tested the concept if the comparison of cellu-
lar activation responses can be used for predicting if EGF
sensitizes nociceptors in behavioral experiments. For
investigating signalling kinetics of endogenous signalling
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base we introduced a quantitative automated microscopy
(QuAM).
Methods
Chemicals
BSA, L-glutamine, poly L-ornithine hydrochloride,
DMSO, paraformaldehyde, Triton X-100 and glutamate
were purchased from Sigma (Taufkirchen, Germany),
collagenase P from Roche (Mannheim, Germany), tryp-
sin from Worthington Biochemical Corporation (Free-
hold, NJ, USA), Neurobasal A (without phenol red), B27
supplement, laminin, minimum essential medium with
glutamax were purchased from Invitrogen (Germany,
UK), DMEM, trypsin and EDTA from Clonetics (Cam-
brex, US) and normal donkey serum from Dianova
(Hamburg, Germany).
Drugs
PMA, EGF, PGE2 and epinephrine were purchased from
Sigma (Taufkirchen, Germany or St. Louis, MO). mNGF
was purchased from Alomone (Jerusalem, Israel), GDNF
was purchased from PeproTech (Hamburg, Germany).
Antibodies
A n t i - P G P9 . 5w a sp u r c h a s e df r o mM o r p h o S y sA G
(Martinsried/Planegg, Germany).
Anti-phospho-Erk (Thr-202/Tyr-204) and anti-phos-
pho-STAT3 (Tyr705) were purchased from New Eng-
land Biolabs (Frankfurt am Main, Germany, f.c. 1:200
and 1:100 respectively). Anti-Erk1/2 (pan) was pur-
chased from BD Bioscience (Heidelberg, Germany, f.c.
1:500) Anti-EGFR and an EGFR-C-terminal peptide
were purchased from Abcam (Cambridge, UK, f.c. Anti-
EGFR 1:500).
Alexa-594-labeled chicken anti-rabbit IgG and Alexa-
633 goat anti-mouse IgG were purchased from Molecu-
lar Probes/Invitrogen (Karlsruhe, Germany; f.c. 1:1000
for immunocytochemistry, 1:500 for immunohistochem-
istry). FITC-coupled anti-mouse IgG was purchased
from Dianova (Hamburg, Germany; f.c. 1:500 for immu-
nocytochemistry and 1:200 for immunohistochemistry).
FITC labeled IB4 (f.c. = 1 ng/μl) and unlabeled IB4 (f.c.
100 ng/μl) were purchased from Sigma (Taufkirchen,
Germany).
DRG-cultures
Cultures of dissociated DRG were prepared from male
Sprague Dawley rats as described previously [31]. The
rats were killed by CO2 intoxication and L1-L6 DRGs
were removed, desheathed, pooled and incubated with
collagenase (final concentration (f.c.) 0.125%; 1 h, 37°C).
T h en e u r o n sw e r ed i s s o c i a t e db yt r y p s i nd i g e s t i o n( f . c .
0.25%, 1176 u, 8 min, 37°C) and triturated with a fire-
polished Pasteur pipette. Axon stumps and dead cells
were removed by centrifugation (5 min, 100 g). Viable
cells were resuspended in 12 ml of NeurobasalA/B27
medium, plated 0.5 ml/culture onto polyornithine/lami-
nin-precoated glass coverslips (12 mm diameter), and
incubated overnight in 24 well plates at 37°C in 5% CO2.
Cell stimulation
After incubation for 15-20 h cells were stimulated with
the growth factors NGF, GDNF, EGF or pharmacologi-
cally with Phorbol 12-myristate 13-acetate (PMA),
respectively. To ensure homogeneous mixture of the sti-
mulants, a volume of 250 μlo u to ft h e5 0 0μlc u l t u r e
medium was removed from the culture well, mixed
thoroughly with the stimulant, and added back to the
same culture. Negative controls were treated alike but
without the addition of any reagent. To reduce mechan-
ical cell stress the stimulus was added very slowly (250
μl in 6 s) using an automatic pipette (Multipette
® pro,
Eppendorf). After treatment, the cells were washed once
with phosphate-buffered saline (PBS) and fixed with par-
aformaldehyde (4%, 10 min) at room temperature (RT).
For staining with the pSTAT3 antibody cells were fixed
and permeabilized with methanol (10 min, -20°C)
Immunocytochemistry
Paraformaldehyde-fixed cells were permeabilized with
0.1% Triton X-100 (10 min, RT), followed by three
washes with PBS (5 min, RT). After blockage of nonspe-
cific binding sites (5% bovine serum albumin (BSA) and
10% normal donkey serum in PBS; 1 h, RT), the cultures
were probed with primary antibodies against target pro-
teins (antibody concentrations against target proteins as
indicated in Methods, Antibodies section) in 1% BSA in
P B S( 1h ,R T ) ,w a s h e dt h r e et i m e s( 1 %B S Ai nP B S ;5
min, RT), and incubated with secondary antibodies (1 h,
RT). After three final washes (PBS; 5 min, RT), the cul-
tures were mounted with Fluoromount-G (Southern
Biotech⁄ Biozol) containing DAPI (0.5 μg/ml). Staining
with the isolectin IB4 from Bandeiraea simplicifolia was
performed in a solution containing 0.1 mM Ca
2+,0 . 1
mM; Mg
2+ and 0.1 mM Mn
2+ i nP B S( 1h ,R T ) ,f o l -
lowed by three washes (0.1 mM Ca
2+,0 . 1m M ;M g
2+
and 0.1 mM Mn
2+ in PBS, 5 min, RT) before mounted
onto microscopy slides with DAPI/Fluoromount-G.
Immunohistochemistry
Prepared L3-L6 DRGs were fixed with paraformaldehyde
( 4 % ,1h ,R T ) ,w a s h e d3 ×w i t hP B S( 2 0m i n ,R T ) ,s a t u -
rated by increasing concentrations of sucrose (10, 20
and 30%, each saturation step overnight, 4°C) and
embedded in Tissue tek
® (EMS Science Services). Mate-
rial was frozen on dry ice and stored at -80°C. DRGs
were cut in 20 μm sections using a Cryostar Cryostat
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The sections were fixed by paraformaldehyde (4%, over-
night, 4°C). Immunostaining was performed as indicated
in the “Immunocytochemistry” section.
QuAM
Cells were evaluated with a Zeiss Axioplan 2 microscope
controlled by the software Metacyte (Metasystems).
Images of 1280 × 1024 pixels were taken using a 10×
objective. The exposure time was defined automatically
so that maximal 1000 pixel/100 μm
2 reached saturation
(i.e. maximal intensity values), but was maximal 0.96s.
For automatic neuron recognition the following para-
meters were defined: size (150 -1500 μm
2), form (aspect
ratio = 2; concavity depth = 0.25), contrast (object
threshold 30%). The integrative pixel intensity of each
selected neuron was normalised against the respective
neuron area and exposure time. The influence of varying
exposure times on the resulting intensity value is insig-
nificant (Additional File 1: Figure S1). For cell identifica-
tion the neuron specific PGP 9.5 immunostaining was
used as independent selection marker. Fluorescence
intensities derived from phospho-Erk1/2 antibody and/
or IB4-signals were quantified on independent color
channels.
Random sampling
Our single cell measurement data are not distributed
normally as they neither pass a normal distribution test
nor a chi-square test. Thus, statistical comparisons of
untreated and treated cultures were performed using a
random sampling approach. “Virtual culture wells” were
created by randomly picking 250, 1000, 5000, 10000 or
20000 cells out of all measured cells and the average
intensity of these virtual wells was computed. Sampling
and computing the average was repeated 10,000 times.
One and the same cell-value could be picked more than
once. The sample mean is, by the Central Limit Theo-
rem, approximately normally distributed, with mean
equal to the population mean.
Confocal microscopy
For evaluation of protein expression confocal images of
cells and sections derived from DRG were taken on an
inverted Zeiss LSM 510 Meta or a Zeiss LSM 700 with
63× or 40× objectives. Plasma membrane staining was
analysed via intensity-histograms with the software Ima-
geJ by measuring the fluorescence intensity profile along
a cell crossing line. The intensity of nucleus localized
pSTAT3 signal was quantified also with ImageJ.
Evaluation of pSTAT3 translocation
Cells were evaluated with a Zeiss Axioplan 2 Imaging
using a 63× oil-immersion objective. Fifty randomly
selected cells per culture were evaluated. Data are
plotted as mean percentage of translocating cells per
evaluated cultures + SEM based on the number of eval-
uated cultures. All counting was done by the same
observer. All treatments have been repeated three times
with DRG-neurons from different rats.
RT-PCR
For RNA extraction DRGs or brain from male Sprague-
Dawley rats were isolated. Total RNA was extracted
using the Nucleospin RNA/Protein Kit (Macherey-
Nagel, Düren, Germany). DNA was digested for 15 min
at 37°C with RQ1 DNAse (Promega, Mannheim,
Germany). RNA was precipitated (0.1 volume 3 M sodiu-
macetate, 2.5 volumes ethanol; 20 min, 20°C and 10 min,
20800 g), washed with 70% ethanol (5 min, 20800 g), dried
and resuspended in RNAse-free water. cDNA was created
using SuperScript III First Strand Synthesis SuperMix for
qRT PCR (Invitrogen, Karlsruhe, Germany). An EGFR-
specific fragment was amplified with specific primers
(5’- CATCCAGTGCCATCCAGAAT - 3’ (forward) and
5’- CTTCCAGACCAGGGTGTTGT - 3’ (reverse)) via
PCR (2 min at 94°C, 30, 35 or 40 cycles of 30 s at 94°C, 30
s at 53°C, 30 s at 72°C and a final step of 10 min at 72°C).
The PCR product was analysed on a 2% agarose gel and
imaged with a Herolab EASY 440K gel documentation
system.
Testing of mechanical nociceptive threshold
The nociceptive flexion reflex was quantified using a
Randall Selitto paw pressure device (Analgesymeter;
Stoelting, Wood Dale, IL), which applies a linearly
increasing mechanical force to the dorsum of the rat’s
hindpaw. The nociceptive mechanical threshold was
defined as the force in grams at which the rat withdrew
its paw. The protocols for this procedure have been
described previously [32,33]. All experiments were per-
formed at the same time of day. In the week preceding
the experiments, rats were familiarized with the testing
procedure at 5 min intervals for a period of 1 h per day
for 3 days. Baseline paw withdrawal threshold was
defined as the mean of six readings before test agents
were injected. Each paw was treated as an independent
measure, and each experiment was performed on a
separate group of rats. Each group of rats was treated
with only one agonist injected intradermally. The noci-
ceptive threshold was measured 30 min after the admin-
istration of the respective reagent. The reagents (see
description in the Results section) were injected as
described previously [34,35].
Statistical Analysis
For statistical comparisons of EGFR fluorescence inten-
sities and pSTAT3 nucleus localized fluorescence
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applied. Statistic analysis of pSTAT3 nucleus transloca-
tion as well as comparison of pErk1/2 and Erk1/2 fluor-
escence intensities between IB4(+)- and IB4(-)-neurons
was done with an one-tailed unpaired t-test. For statisti-
cal comparison of NGF and GDNF treated vs. untreated
cultures the sample mean resulting from the random
sampling approach were tested by an one-tailed
unpaired t-test. Statistic analysis of behavioral data was
done with one-way ANOVAs followed by Dunnett’st e s t
for comparisons with one control value. P < 0.05 was
considered as statistically significant.
Results
Software-based identification of dissociated DRG-neurons
The heterogeneity of primary DRG-neuron cultures
challenges the first step of a quantitative image analysis,
the object identification. The DRG-neurons, but not
axon stumps or glia cells have to be identified by setting
suitable “object identifier” parameters in the image-
analysis software. Images of immunofluorescently
labeled dissociated DRG-neurons culture were taken by
an automated microscope (Figure 1A) and neurons
identified by the image analysis software “Metacyte”
(Metasystems). Neurons were visualized with an anti-
body against the neuronal marker PGP 9.5. Object iden-
tification parameter optimization was performed and
allowed the identification of neurons based on object
size (150-1500 μm
2), roundness (ratio of longest to
shortest diameter < 2), smoothness of cell perimeter
(concavity depth < 0.25), and relative PGP 9.5 immuno-
fluorescence intensity (> 30% difference to the sur-
rounding) (Figure 1B).
In the culture 16 ± 1% of all cells identified visually as
neurons based on their shape and neuronal marker PGP
9.5 expression were in cell clusters. These clustered cells
were rejected as cells function very differently if cultured
as separate cells or connected to others. Further 3 ± 2%
of all neurons were cut by the viewfield borders of the
images and were therefore also rejected. Of the remain-
ing 81% of all neurons in culture, 93 ± 2% were detected
by the software indicating a very robust and well opti-
mized detection algorithm.
Single DRG-neuron based studies require large number of
analyzed cells per treatment
One signalling component important in nociceptor sen-
sitization is the MAP-kinase Erk1/2 [36]. Activation of
Erk1/2 is commonly detected by use of antibodies speci-
fic for the Thr-202/Tyr-204 phosphorylation site of
Erk1/2. We tracked the basal phosphorylation Erk1/2
signals in untreated cultures with basal levels of activa-
tion and investigated 49,502 single cells. The degree of
immunofluorescently detected phosphorylation shows
an intensity distribution with a standard deviation of ±
180%.
Considering the high standard deviation of intensities
we next determined, how many cells have to be mea-
sured to describe the distribution sufficiently and what
level of sensitivity is reached thereby.
One can estimate, how good the “real” distribution is
detected by comparing the distribution of culture wells
with small numbers of cells with the distribution of a
very large number of measured cells. To do so, out of
49,502 measured unstimulated cells we randomly
sampled 10,000 artificial cultures consisting each of 250,
1000, 5000, 10,000 and 20,000 cells per virtual well,
respectively (Figure 1C). As expected, sampling more
cells per culture resulted in an ever-narrowing degree of
deviation of mean-culture-intensities. For 250 cells the
standard deviation of the mean is +/- 11%, for 1000 +/-
6%, for 5000 and 10,000 cells +/- 2%, and for 20,000
cells +/- 1%. This indicates, that mean culture intensity
changes below 22% (two times standard deviation)
intensity change cannot be assumed statistically sound if
only 250 cells are investigated. Of note, an intensity
increase in only a subgroup of e.g. 1/5 of the cells,
requires with 250 measured cells per culture an increase
of at least 5 × 22% = 110%, i.e. roughly a doubling of
the intensity, within the subgroup to result in an overall
mean change of 22%. But investigation of more cells
allows the detection of smaller changes even down to
some few percent change (standard deviation for 10,000
measured neurons = +/- 2%) indicating high sensitivity
of our relative immunofluorescence approach despite
the apparent huge heterogeneity of DRG-cultures.
Subgroups can be defined by classical expression
markers
In most published reports of immunofluorescently-labeled
marker-protein-based subgroups, the categorization into
“marker-positive” and “marker-negativ” is performed by a
trained experimenter judging by eye [2,3,37]. This assumes
a clear distinction between the positive and the negative
cells. This assumption nevertheless has never been tested
thoroughly.
One well established marker for such a DRG-neuron
subgroup is the isolectin B4 (IB4) identifying preferably
non-peptidergic GDNF-dependent nociceptive C fibers.
Thus we measured the intensities of single cells labeled
with IB4. The intensities showed a continuum of intensi-
ties (Figure 1D). Thus the assumption of clearly separated
intensity ranges for marker-positive and marker-negative
cells is not valid.
Nevertheless, representing the data by an intensity his-
togram one is tempted to differentiate one population in
the lower intensity range (large peak on the left) and a
shallow but widespread distribution with much higher
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Figure 1 Automatic DRG-neuron identification and quantification of phosphospecific fluorescence intensities. A) Example image of a
microscope view field of the DRG neuron culture immunofluorescently labelled for the neuronal marker PGP9.5. Neurons show high degree of
heterogeneity in respect to size, fluorescence intensity and extend of cell-cell contacts. B) Examples of objects selected as neurons (upper two
rows) and rejected objects (lower two rows). Rejected objects include non-cellular debris, glia cells and clustered neurons. C) “Virtual wells” were
created by randomly selecting 250, 1000, 5000, 10,000 or 20,000 cells per virtual well out of 49,503 measured cells. The normalized mean well
intensity of 10,000 such virtual wells with the respective standard deviation is depicted indicating the sensitivity limit of studies based on the
various average cell numbers per well (250 cells per well resulted in a well Mean Intensity of 1.0005 ± 0.1133, 1000 cells in 1.0003 ± 0.0564, 5000
cells in 0.9999 ± 0.0240, 10,000 cells in 0.9997 ± 0.0159, and 20,000 cells result 0.9998 ± 0.0098). D) IB4 lectin derived fluorescence intensities
showed a continuous distribution of intensities. Coincubation with uncoupled lectin to block specific binding resulted in an intensity histogram
(n = 5002 cells, black line) matching the first peak of the unblocked IB4-intensity histogram (n = 23266 cells, red line) identifying these cells as
unspecificly binding and thus as IB4(-)-cells. E) Diameter histogram of 49,503 neurons (yellow bars). 40,706 neurons were labeled for IB4. IB4
(+)-neurons (red bars) show a higher average diameter than IB4(-)-neurons (blue bars). F) Comparison of the normalized Mean Intensity of
phosphorylated and total Erk1/2 in IB4(+)- and IB4(-)-neurons (n = 1421 IB4(+)-neurons and n = 963 IB4(-)-neurons). IB4(+)-neurons show a
higher amount of pErk1/2 but also a higher expression rate of Erk1/2 in comparison to IB4(-)-neurons (p < 0.001).
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unlabeled lectin we tested, if the low intensity popula-
tion represents unspecific binding of the lectin and thus
is the marker-negative population. The competitive
block eliminated all specific IB4-signal and resulted in
ablation of the higher intensity part of the histogram. By
taking the point of intersection of both intensity histo-
grams as cut-off we identified the two distributions as
IB4 positive and IB4 negative neurons (Figure 1D). Ana-
lysis of 40,706 cells identified 71 ± 8% to be IB4(+)- and
29 ± 8% to be IB4(-)-neurons.
The IB4(+)-subgroup shows higher basal Erk1/2
phosphorylation
The potential strength of the quantitative immunofluor-
escence and single cell based analysis of the heteroge-
nous culture is that one can analyze marker defined
subgroups in depth by parameter combination indepen-
dent of other cells in the very same culture. We per-
formed double staining detecting on one hand the static
subgroup marker IB4. On the other hand with antibo-
dies directed against phosphorylated i.e. activated Erk1/2
we investigated the dynamic activation state of Erk1/2.
The classified IB4(+)- and IB4(-)-neurons were com-
pared in respect to their size and basal level of Erk1/2
phosphorylation. The majority (63%) of IB4(+)-neurons
have diameters in the range between 22-32 μmw h e r e a s
most IB4(-)-neurons seem to be smaller as 60% have
diameters between 14-24 μm (Figure 1E).
We thereby describe not only a size difference
between IB4(+)- and IB4(-)-cells but we detected for the
first time a difference in the basal level of Erk1/2 phos-
phorylation. In IB4(+)-cells the mean intensity of pErk1/
2 is measured to an intensity value of 1.12 ± 0.01 (Mean
± SEM) versus 0.82 ± 0.001 (Mean ± SEM) in IB4
(-)-cells (Figure 1F). Interestingly, the increase in phos-
phorylated Erk1/2 is matched by an increase in total
Erk1/2 expression. Thus, while the relative amount of
activated Erk1/2 appears to remain constant, the total
amount, i.e. the concentration of activated Erk1/2 per
cell increases.
Functional subsets of neurons can be defined by growth
factor induced increases of pErk1/2 intensities on a single
cell level
Above, we established the single neuron-based quantitative
automated microscopy (QuAM) for unstimulated cultured
DRG-neurons. Next we tested for detection of pErk1/2
intensities in response to known activators of Erk1/2, NGF
and GDNF. In behavioral tests NGF- and GDNF-induced
mechanical hyperalgesia was found to depend on activation
of Erk1/2 [19,22]. Comparing the fluorescence intensities
averaged over all neurons (n = 5203 cells for no stimulus,
n = 3778 cells for NGF treatment, n = 1275 cells for
GDNF treatment) we detected significant increases in
Erk1/2 phosphorylation levels of about 6-fold after NGF
treatment and of about 4-fold after GDNF treatment,
respectively (Figure 2A).
Analysis of the data on a single cell base allowed dee-
per evaluation. The variability of the stimulated neurons
was much larger than in the unstimulated cultures. Plot-
ting the single neuron intensities of pErk1/2 in a scatter
blot revealed increased intensities of up to 100-fold over
average intensities of unstimulated cultures (Figure 2B).
Nevertheless, a large number of cells showed intensities
similar to the unstimulated neurons and thus were con-
sidered “non-responsive”.
To test if all cells have the potential to be activatable
we stimulated the culture with PMA. Phorbol esters
such as PMA are very strong stimulants of Erk1/2 acti-
vation irrespective of upstream receptor expression.
Therefore PMA stimulation should activate Erk1/2 in all
cells. But PMA stimulation should allow also evaluation
of the maximal responsiveness of sensory neurons as
inactivation due to negative feedback loops should be
circumvented. We found PMA stimulation of DRG-neu-
rons to result in a complete shift of the pErk1/2 inten-
sity histogram to higher intensities compared to the
histogram of untreated cultures confirming that PMA is
a strong Erk1/2 activating stimulus (Figure 2C).
To differentiate for each single neuron if it is activated
or not, one can take the intersection between the inten-
sity histogram of the unstimulated control cells and the
stimulated cells as threshold value. While this will result
in some false negatives this estimate is conservative in
respect to the classification of truly positive i.e. activated
neurons and thus allows deeper evaluation of para-
meters for activated neurons. Applying this method to
PMA treated DRG-cultures we detected that single neu-
ron intensities are for 92 ± 6% of the neurons higher
than the intensities of unstimulated neurons (Figure
2C). This supports the previous assumption that PMA
can activate Erk1/2 in all neurons.
T h ec o m p a r i s o no fh i s t o g r a m so ft r e a t e da n d
untreated neurons allowed the definition of NGF and
GDNF responsive neurons. We detected only 50 ± 8%
NGF and 47 ± 8% GDNF responding cells, respectively,
reflecting subgroup specific activation patterns (Figure
2c).
Next we compared the subgroups of NGF and GDNF
responding cells in respect to their size. For NGF-
responding cultures especially cells sized between 200
and 500 μm
2 were activated (Figure 2D). In contrast the
GDNF responding cells had more frequently a size
between 300 and 600 μm
2 (Figure 2E), suggesting that
NGF and GDNF activate different cell populations.
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Figure 2 NGF and GDNF stimulation leads to Erk1/2 phosphorylation in subpopulations. A) Stimulation with NGF (1 nM, 30 min) and
GDNF (1 nM, 30 min) led to significant increase of pErk1/2 intensity levels (n = 5203 cells for no stimulus, n = 3778 cells for NGF treatment, n =
1275 cells for GDNF treatment, error bars are SEM, p < 0.001 for NGF/GDNF vs control). B) 1D scatter plot of the single cell data plotted in A) as
bar graphs. Thereby, the huge heterogeneity with up to 100-fold intensity differences is clearly visible. C) Intensity histogram of unstimulated
(black line), NGF (red line), GDNF (blue line) and PMA (orange line) stimulated DRG-cultures. Stimulation led to increased numbers of cells with
higher fluorescent intensities. PMA activates Erk1/2 in virtually all neurons as nearly no cells remain with intensities of the control condition. D),
E) Cell size profile of NGF/GDNF responding and non-responding cells. Responding neurons tend to be smaller in size. F), G) IB4 fluorescence
intensity profile of NGF/GDNF responding and non-responding cells. NGF responding neurons tend to low intensity IB4 labeling while GDNF
responding cells are mostly strongly IB4 labeled. H) Kinetic of NGF/GDNF induced Erk1/2 phosphorylation (n = 1000-4000 cells per time point,
error bars SEM).
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Page 8 of 16Subgroup specific activation of Erk1/2 can be defined
through additional subgroup markers such as IB4
NGF and GDNF function has been shown to correlate
with subgroup markers [16,19,38]. We employed the
marker for GDNF-responsive neurons, the lectin IB4.
The pErk1/2 and the IB4 fluorescence for each neuron
were measured (Figure 2F, G). We analyzed the sub-
groups of NGF and GDNF responsive neurons in
respect to the IB4 label intensity. The IB4 intensity his-
togram of NGF responding cells peaked at lower IB4
intensities indicating that most NGF responding cells
are IB4 negative (Figure 2F). In contrast the IB4 inten-
sity histogram of GDNF responding cells show less cells
at lower but more at higher IB4 intensity level indicating
IB4(+)-cells to be GDNF responsive (Figure 2G).
NGF and GDNF induced pErk1/2 kinetics differ on a single
cell base
Cells do not only differ in terms of baseline activity and
responsiveness to stimuli. A very important parameter is
also the pace of activation and signal transduction. As
we now have established a technique to monitor the
phosphorylation of Erk1/2, we therefore recorded next
the kinetics of Erk1/2 activation on single neuron base.
Beyond attempting a technical prove of principle this is
also functionally of interest. As indicated in the intro-
duction differential signalling kinetics of Erk1/2 can
result in diametrically opposed cellular phenotypes
induced by NGF versus EGF, respectively. Thus, for elu-
cidating signalling mechanism it is not only important
to investigate if but also when, how long, and how
strong a kinase is activated [29,39].
We recorded for the first time the kinetics of endo-
genous Erk1/2 activation induced by the two sensitizing
and receptor tyrosine kinase dependent growth factors,
NGF and GDNF in primary DRG neurons. NGF showed
a maximal Erk1/2 phosphorylation after 15 min main-
taining a sustained high phosphorylation status there-
after (Figure 2H). Also GDNF resulted in
phosphorylation of Erk1/2. Nevertheless, GDNF treat-
ment resulted in a shallower kinetic curve representing
a less strong and slower Erk1/2 activation than after
NGF stimulation (Figure 2H).
EGFR is expressed in DRG-neurons
We analyzed so far baseline activity of DRG-neuron
subgroups and the activation kinetics in response to the
sensitizing growth factors NGF and GDNF. This techni-
que opens the door to elucidate the influence of other
growth factors on Erk1/2, which are so far not described
in the context of pain sensitization like EGF.
First we tested, if EGF can potentially act directly on
the nociceptive neuron by checking for expression of
the EGF receptor (EGFR) in DRGs. RT-PCR showed an
amplification of an EGFR specific fragment at the
expected size indicating that EGFR is expressed on the
level of mRNA (Figure 3A) in rat DRG (rat brain serving
as positive control [40]).
But in DRGs there are also other cells than neurons
such as glia and stellate cells. Thus, we analyzed the
expression of EGFR in DRG-sections and dissociated
DRG-neuron cultures using immunofluorescence micro-
scopy (Figure 3B, C). DRG-sections as well as neuronal
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Figure 3 EGFR is expressed in DRG-neurons. A) Analysis of EGFR
mRNA expression in lysates of DRG and brain from male rats by RT-
PCR. RT-PCR shows a DNA-fragment with increasing intensity in
dependence of the number (30, 35 and 40) of amplification cycles
for DRG (lane 1-3) and brain (lane 6-8). Lane 4 and 9 reaction
without reverse transcriptase (-RT) and lane 5 and 10 water control.
B) Confocal images of DRG-sections. Left panel EGFR-staining,
middle panel EGFR + blocking peptide, right panel secondary
antibody control leaving out the primary antibody. C-terminal EGFR
antibody blocking peptide was used in a 100× higher concentration
than the antibody. C) Confocal images of DRG-cultures. Left panel
EGFR-staining, middle panel EGFR + peptide, right panel secondary
control. C-terminal EGFR antibody blocking peptide was used in a
100× higher concentration than the antibody. Intensity profiles
along the indicated line crossing the cells indicate the plasma
membrane staining of the EGFR-antibody. EGFR-C-terminal blocking
peptide abolished the plasma membrane EGFR-signal D) QuAM
quantified intensity histogram of EGFR-stained cultures (red), EGFR +
blocking peptide (blue) and secondary control (black) indicated that
EGFR is expressed in all neurons (n = 1874 cell for secondary
control, n = 1720 cells EGFR, n = 1705 cells for EGFR + blocking
peptide; p < 0.001).
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Page 9 of 16cultures showed higher fluorescence intensities and in
case of cultures also a membrane located immunofluor-
escence signal if probed with an EGFR-specific antibody.
EGFR-signals were detected in axonal fibers, glia-cells as
well as in the DRG-neurons. To test antibody specificity
we preincubated the EGFR-antibody with a blocking
peptide. We observed a reduction of EGFR derived
fluorescence intensities specifically in neuronal cell
bodies and glia cells but not in the axonal fibers (Figure
3C). This identifies the cell body staining as specific
while disregards the fiber staining as unspecific.
We also quantified the immunofluorescence intensities
in DRG-cultures using QuAM (Figure 3D). The EGFR
stained neurons showed significantly higher intensities
than the cells stained only by the secondary antibody or
by the EGFR antibody preincubated with a 100× higher
concentration of the blocking peptide. There was a com-
plete shift to higher intensities of the intensity histo-
grams of EGFR stained cells compared to cells stained
in presence of the blocking peptide. This indicated that
in every single cell the EGFR-antibody derived intensity
was higher than in the control cells. This suggests that
EGFR is expressed not just in a subpopulation but in all
DRG-neurons (Figure 3D).
Phosphorylation of Erk1/2 differs strongly between NGF/
GDNF and EGF treated neurons
We next investigated if we could detect an EGF induced
increase in phosphorylation of Erk1/2. Because EGFR
seemed to be expressed in all DRG-neurons (in contrast
to the GDNF or NGF receptors described to be
expressed only in a subset of cells [16,41]) we expected
more EGF than NGF or GDNF responding cells. There-
fore EGF stimulation should result in a higher number
of cells showing an increasing pErk1/2 signal than in
response to NGF or GDNF stimulation. Nevertheless,
using 1 nM EGF we could not observe any pErk1/2 sig-
nal above baseline in contrast to stimulation with 1 nM
NGF or 1 nM GDNF.
We tried different time points of stimulation but with
our current limit of sensitivity we could not detect any
signal difference in comparison to the baseline signal
(Figure 4A). 5 min EGF stimulation is reported to induce
a maximal Erk1/2 phosphorylation in HeLa- cells [42] or
PC12 cells [43]. Also stimulation times of 10 min are fre-
quently used to detect Erk1/2 phosphorylation for exam-
ple in astrocytes [44], fibroblast [45], kidney epithel cells
[46] or Sertoli cells [47]. Thus, we tried different concen-
trations of EGF and stimulated for 5 min and 10 min
(Figure 4B). But in contrast to NGF/GDNF, there is no
EGF induced activation of Erk1/2 detectable in the het-
erogeneous system of DRG-neurons. Also starvation
prior to EGF stimulation did not result in EGF induced
Erk1/2 phosphorylation (data not shown).
To test if EGF initiates signalling in nociceptive neu-
rons via a pathway different than the Erk1/2 pathway,
we tested for the phosphorylation and translocation of
the transcription factor STAT3. Indeed, stimulation of
the nociceptive neurons with EGF (1 nM) for 15 min
resulted in an increase of neurons showing pSTAT3 in
the nucleus (Figure 4C). In addition, quantifying the
intensity of pSTAT3 in EGF-treated versus untreated
cells indicates a clear increase of the nuclear pSTAT3
signal (Figure 4D). Thus, apparently EGF does initiate
signalling in DRG neurons but does not initiate phos-
phorylation of Erk1/2.
EGF does not induce mechanical hyperalgesia
In our cell biological experiments we observed the cul-
tured neurons to react differently to EGF than to NGF
and GDNF stimulation, the former not activating Erk1/2
while the latter two leading to a sustained Erk1/2 phos-
phorylation. Therefore we hypothesized that EGF in
contrast to NGF and GDNF will not lead to mechanical
hyperalgesia. Intradermal injection of NGF and GDNF
induces strong hyperalgesia as measured by the Randall-
Selitto paw pressure test [19,22]. Indeed, as predicted
from our cellular studies, intradermal injection of EGF
or the physiological relevant EGFR agonist heparine
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Figure 4 EGF induces STAT3 translocation but not Erk1/2
phosphorylation. A) Kinetic of phosphorylation of Erk1/2 in
response to 1 nM EGF treatment of DRG-neurons (n = 1000-2000
cells for each time point, error bars SEM). B) Dose response curve
after 5 min or 10 min stimulation (n = 1000-3000 cells for each
concentration, error bars SEM). C) 1 nM EGF induced
phosphorylation and translocation of STAT3 into the nucleus of
DRG-neurons. D) Quantification of neurons showing phosphorylated
STAT3 in the nucleus in response to 1 nM EGF (p < 0.01; n = 300
cells per condition were counted in 3 independent experiments). E)
Mean intensity of pSTAT3 increased in nuclei of neurons in
response to 1 nM EGF treatment (p < 0.01; Mean intensity of nuclei
(61 (control) and 83 (EGF treated)) were quantified in 3 independent
experiments).
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Page 10 of 16bound EGF (Hb-EGF) led not to an establishment of
mechanical hyperalgesia (no significant reduction of
paw-withdrawal threshold by 8.5 ± 4.1% (or 3.6 ± 1.9%
in other data series) after EGF treatment (n = 6) and 3.0
± 1,8% after Hb-EGF (n = 12) (Figure 5).
EGF inhibits PGE2 induced mechanical hyperalgesia
In PC12 cells NGF and EGF treatment evoked opposing
responses, differentiation versus proliferation, respec-
tively. Comparing EGF and NGF effects in pain sensiti-
zation we found that EGF in contrast to NGF treatment
lead not to mechanical hyperalgesia. But absence of a
response is unsatisfying. Accordingly, we tested if EGF
treatment follows the example of PC12 cells and thus
does the opposite of the NGF treatment. In the context
of pain the opposite of “sensitization” is “block of sensi-
tization”. One classical inflammatory mediator resulting
in sensitization is prostaglandin E2 (PGE2) [48]. Thus
we tested, if pretreatment with EGF/Hb-EGF can block
PGE2 induced mechanical hyperalgesia. Indeed EGF as
well as Hb-EGF significantly abolished PGE2 mediated
mechanical pain sensitization (reduction of paw-
withdrawal threshold of EGF-data-series by 33.0 ±3.8%
after PGE2 treatment, 2.6 ± 1.3% after EGF+PGE2,( f o r
all treatments n = 6); reduction of paw-withdrawal
threshold of Hb-EGF-data-series by 36.0 ± 0.8% after
PGE2 treatment, 3.6 ± 2.9% after Hb-EGF+PGE2,( f o ra l l
treatments n = 6)).
To investigate, if EGF shows general analgetic func-
tions, we pretreated animals with EGF and Hb-EGF
before injecting epinephrine. Epinephrine is an agonist
of the b2-adrenergic receptor and described to induce
mechanical hyperalgesia. In contrast to PGE2 induced
mechanical hyperalgesia, EGF does not block the epi-
nephrine mediated decrease of the nociceptive threshold
(reduction of paw-withdrawal threshold of EGF-data-
series by 36.2 ± 1.8% after epinephrine and 35.9 ± 1.5%
after EGF+epinephrine; reduction of paw-withdrawal
threshold of Hb-EGF-data-series by 38.6 ± 2.9% after
epinephrine and 35.6 ± 1.7% after Hb-EGF+epinephrine
(n = 6)).
Discussion
Investigation of heterogeneous DRG-neurons requires a
defined quantitative microscopic approach
Standard methods to monitor the activation of signalling
cascades like the Erk1/2 pathway are Western-Blot-ana-
lysis and ELISAs. Using these techniques cells are lysed
and therefore information about single cells and sub-
groups is lost [49-51]. On the other hand, single cell
based techniques such as FACS are not suitable for
adherent cells. QuAM overcomes this problem. The
establishment of such a quantitative microscopy
approach provides two challenges: Neuron identification
and quantification of fluorescence-derived signals. The
automatic neuron recognition was challenged by the
presence of glia-cells, fibroblasts and axon stumps in the
DRG-culture. Nevertheless, the relative simple geometry
of the cultured sphere-like neurons allowed the auto-
matic detection of nearly all neuronal marker PGP 9.5
expressing neurons. Size and size distribution of the
identified neurons resembles nicely published data [52].
Due to the automation, a large number of cells can be
evaluated on a single cell base. Thereby, the distribution
of the respective parameter can be exactly described.
This allows evaluation, if the intrinsic assumption of the
classical “eye-based” evaluation holds true, that a “mar-
ker-positive” and a “marker-negative” group can easily
and clearly be separated as their respective intensity dis-
tributions are not or only slightly overlapping. Our first
quantitative measurement of two such parameters, the
phosphorylation status of Erk1/2 and the classical sub-
group-marker, IB4 binding, shows clearly, that this
assumption is not true. Thus, for any marker it is essen-
tial to define the distribution pattern and the respective
threshold criterion to distinguish positive and negative
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Figure 5 EGF blocks PGE2 induced mechanical hyperalgesia.
Intradermal injection of 1 μg EGF and 1 μg Hb-EGF led not to a
significant decrease in the nociceptive threshold in contrast to
intradermal injection of 100 ng PGE2 or 100 ng Epinephrine. EGF
and Hb-EGF abolished subsequent PGE2 but not epinephrine
induced sensitization (p < 0.001). Reduction of paw-withdrawal
threshold in EGF/PGE2 data series by 3.6 ± 1.9% after EGF treatment,
33.0 ± 3.8% after PGE2 treatment, 2.6 ± 1.3% after EGF+PGE2.( n=
6). Reduction of paw-withdrawal threshold in EGF/epinephrine data
series by 8.5 ± 4.1% after EGF treatment, 36.2 ± 1.8% after
epinephrine and 35.9 ± 1.5% after EGF+epinephrine (for all
treatments n = 6). Reduction of paw-withdrawal threshold in Hb-
EGF data series (3.0 ± 1.8% after Hb-EGF (n = 12), 36.0 ± 0.8% after
PGE2 treatment, 3.6 ± 2.9% after Hb-EGF+PGE2, 38.6 ± 2.9% after
epinephrine and 35.6 ± 1.7% after Hb-EGF+epinephrine (for all
treatments n = 6)).
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Page 11 of 16cells. This result calls into question the validity of many
of the published marker based subgroup quantifications.
Analysing the intensity distribution of the basal level
of Erk1/2 phosphorylation, we find a very high degree of
variability in the range of 180% and more. Nevertheless,
despite the wide distribution we show that in principle
subtle differences of a stable parameter such as size or
m a r k e r - e x p r e s s i o na sw e l la sc h a n g e so faf l u c t u a t i n g
parameter such as activation state even as little as a 2%
change (averaged over all cells) can be detected. Thus,
the sensitivity of this quantitative approach is much
increased over the current threshold based “by eye” ana-
lysis. In the latter case, one cannot evaluate for small
shifts of distributions but rather is dependent on inten-
sity increases in the range of multiples of the distribu-
tion deviation (e.g. 2 times 180%).
One problem central of heterogeneous systems is that
one has to estimate the required sample size to reliably
represent the whole divergent population. We find ran-
dom sampling to nicely determine, how many cells have
to be evaluated for which degree of sensitivity. Detection
of changes such as a 22% of mean whole culture inten-
sity requires a formidable number of 250 cells. Robust
but subgroup specific changes require even more. For
example, a 50% intensity increase in 1/5
th of the whole
culture would result only in a whole culture intensity
change of 10%. Thus, 1000 cells and more are required
for detection.
To our knowledge our approach gives for the first
time a rational to determine the required number of
DRG-neurons to be evaluated. Our results also indicate
the necessity to move forward to an automated quanti-
tative high content analysis of this cellular system as
manual counting of such large numbers of cells is in
addition to being unreliable also extremely time
consuming.
Why to investigate endogenous signalling cascades
Most studies investigating e.g. growth factor induced
signalling assume full responsiveness of all neurons
expressing the respective growth factor receptor. But is
this necessarily true? Recently, we showed responsive-
ness to ligands of the b2-adrenergic receptor to occur
only in a subset of sensory neurons. Interestingly, while
all neurons appear to express the receptor, only about
15-20% of the neurons responded by activation/translo-
cation of the protein kinase C epsilon (PKCε) [31].
Interestingly, the number of responsive neurons could
not be increased by circumventing the cascade initiating
receptor by directly activating the downstream compo-
nent Epac. Thus, while signalling cascades, of course,
require the expression of a suitable receptor and its
downstream components, this is not sufficient for ligand
initiated signalling. We thereby gave proof of principle
of a first IB4(+)-neuron specific signalling mechanism,
which is not defined by receptor expression but by regu-
lation of downstream signalling [31].
To what extent intracellular signalling depends on the
cellular context only starts to emerge. One of the few
other examples in nociceptors is the stunning effect of a
NaV1.7 mutation. The very same point mutation
resulted in a gain of function phenotype for nociceptive
neurons but in a loss of function phenotype for sympa-
thetic neurons [53]. Again, the cellular context defined
in a drastic way the phenotypic result.
Detailed knowledge of context dependence for indivi-
dual signalling pathways in single cells is so far rare in
cell biology. Nevertheless, in non-nociceptive systems on
aw h o l ec u l t u r eb a s et h e r ea r es o m es t u d i e sd e s c r i b i n g
the signalling outcome to depend on the time, subcellu-
lar location and intensity of Erk1/2 activation [39]. A
weak Erk1/2 signal in carcinoma cells led to apoptosis
whereas a strong signal is related to cell survival [54].
Proliferation of fibroblast and differentiation of PC12
cells was proven to depend on localized signalling i.e.
the translocation of Erk1/2 to the nucleus [55,56]. And
in our eyes most stunningly, transient Erk1/2 activation
results in proliferation, whereas sustained phosphoryla-
tion of Erk1/2 induced the opposite, namely differentia-
tion of PC12 cells [29].
Thus, the description of signalling pathways and their
kinetic properties does not merely fill a gap between sti-
mulus input and effector output. To the contrary, it
describes a complex computational mechanism which
rules over effector activity in a non linear manner.
Erk1/2 activation can define nociceptor subgroups
We have established with QuAM a technique with sin-
g l ec e l lr e s o l u t i o n ,w h i c hi sa b l et oc o r r e l a t ean u m b e r
of cellular parameters with quantitative temporal and
spatial resolution. To establish the ability to differentiate
subgroup specific signalling we detected the phosphory-
lation level of the MAP kinase Erk1/2. Already in their
basal state we find for the first time an indication, that
IB4(+)-neurons differ in respect to their signalling sta-
tus. The basal levels of Erk1/2 and more importantly for
signalling also of phosphorylated Erk1/2 is much
increased in IB4(+)- versus IB4(-)-neurons. As Erk1/2
has been shown to regulate a number of ion channels
important in nociceptive signalling, this suggests a
potential difference in basal ion channel properties.
Indeed functional differences between IB4(+)- and IB4
(-)-neurons have been reported. For example, the slow
inactivation properties and the use-dependent inhibition
of the voltage gated sodium channel NaV 1.8 are differ-
ent depending on the expression of NaV 1.8 in either
subgroup [57]. Some attempt to attribute the differences
to differential ion channel expression [58]. But the
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functionality of sensory neurons [9]. Thus, the altered
basal activity status of Erk1/2 now detected by us, might
indicate even beyond transcriptional/translational differ-
ences a novel reasoning for the observed differential
functionality of IB4(+)-neurons, namely distinct signal-
ling states.
We detected pErk1/2 levels also after treatment with
the growth factors NGF, GDNF and EGF. The quantifi-
cation of fluorescence intensities derived from phospho-
specific antibodies in the obtained neurons showed
indeed that stimulation with the growth factors NGF
and GDNF lead to an increase in the phosphorylation
signal of Erk1/2 in DRG-neurons but again only in sub-
groups of these sensory neurons. Our result of 50 ± 8%
NGF-responding cells lay in the range of expression
data for the NGF receptor TrkA, which is reported to
be expressed primarily in peptidergic (IB4(-)) neurons
[41]. The receptor for GDNF is a complex of a ligand
binding domain GFR1-3 and the signal transducing
transmembrane protein, RET, and is expressed in a sub-
group of non-peptidergic (IB4(+)) neurons [16]. The
subgroup size of IB4(+)-neurons differs in the literature
from 40 - 70% most likely due to the semi-qualitative
evaluation of a subjective experimenter [3-5]. Thus, our
results of 71 ± 8% IB4(+)-cells and 47 ± 8% GDNF
responding cells are in the range of published IB4-bind-
ing patterns and GDNF receptor expression data. In line
with [2,3], which suggest that there is an overlap
between IB4(+)- and CGRP/TrkA(+)-neurons, we
observed a NGF response not exclusively in IB4(-)-neu-
rons but also in IB4(+)-neurons. In contrast, the GDNF
response was restricted with 90% nearly exclusively to
IB4(+)-cells. After this proofo fp r i n c i p l eo u rq u a n t i t a -
tive approach now opens the door to describe new sub-
populations on a novel base, namely on the base of
signalling cascade activity.
Growth factor signalling differs strongly in DRG-neurons
We could validate that our high content analysis and cell
biology approach can help to elucidate roles for non
investigated physiological relevant components such as
the wound healing mediator EGF. It can help to formu-
late models for mechanisms of the sensitizing process
and to explain behavioral phenotypes by gathering path-
way activation data. The results were surprising. In con-
trast to the growth factors NGF and GDNF, EGF failed
to induce Erk1/2 phosphorylation even though the EGFR
is expressed in all DRG-neurons and the STAT3 signal-
ling pathway is initiated by EGF in DRG-neurons. Com-
monly, receptor tyrosine kinase signalling is taken
synonymous with Erk1/2 activation. But this might be a
literature bias. Indeed, while there is strong pressure to
report cellular responses to EGF in EGFR expressing
cells, also other studies show EGFR expression [59,60] in
adult DRG but fail to detect EGF induced Erk1/2 signal-
ling activity in cell culture. Nevertheless, the EGFR ago-
nists amphiregulin [61] and transforming growth factor
[62] exert a clear survival effect. Along the same line, in
developing P7-P9 DRG-neurons a slight increase in the
phosphorylation signal of Erk1/2 after 5 min EGF stimu-
lation could only be observed if using a tertiary antibody
incubation step for additional signal amplification [63].
Not to forget, commonly even in clearly EGF responsive
cell lines long-term starvation of the cells is prerequisite
for signal detection (something not successful in nocicep-
tive neurons (data not shown)). This indicates that while
physiologically effective EGF induced signalling is not
necessarily dependent on Erk1/2 activation. What is clear
from our analysis is that the receptor tyrosine kinase
induced signalling cascade toward Erk1/2 is activated
fundamentally differently if initiated by EGF versus NGF
and even GDNF. This indicates that growth factor func-
tion is growth factor specific in DRG-neurons.
Role of EGF in pain can be predicted by QuAM
Our study proves, that the investigation of cellular sig-
nalling events can indicate a behavioral phenotype. As
in the cellular experiments, EGF does not follow the
growth factors NGF and GDNF and thus does not result
in sensitization. In contrast and in correlation to obser-
vations in PC12 cells, EGF results in a phenotype oppos-
ing the one induced by NGF. Interestingly, EGF inhibits
PGE2 but not epinephrine induced mechanical hyperal-
gesia. This argues against an unspecific effect of EGF
such as general dampening of nociceptor activity. PGE2
is described to induce hyperalgesia by activation of PKA.
In contrast epinephrine sensitizes only partly by activa-
tion of PKA but by activation of PKCε and Erk1/2
[34,48,64,65]. Which downstream signal of EGF induces
this block has to be investigated in future. Nevertheless,
our results are further proof that signalling cascades
cannot be simply transferred from one cellular system
to the next. Further signalling pathway outputs are
highly stimulus dependent, even though it might involve
similar components such as receptor tyrosine kinases
like in the case of EGF, NGF and GDNF. QuAM eluci-
dates these NGF/GDNF and EGF signalling differences
and explains thereby the contrary behavior of these in
inflammation physiological relevant growth factors.
With pain mechanisms one has to reflect about the
potential use in humans. Are there indications for a
similar action of EGF in humans? We believe so. If clini-
cal studies of cancer patients treated with an EGFR inhi-
bitor are analysed, one finds clear reports of therapy
induced abdominal, chest and generalized pain [66-69].
This suggests that also in humans the presence of EGF
is able to dampen nociception, as indicated by our
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ently results in the patient in a removal of this break
thereby inducing heightened sensitivity and pain.
Conclusions
We established a microscopy based approach to detect
the activation of endogenous signalling pathways on sin-
gle cell level. Differences between stimulus responses
could be analysed not only qualitatively but also quanti-
tatively. This allowed us to define neuronal subgroups
based on their signalling status in contrast to the com-
mon expression marker based subgrouping. Further, we
found single cell derived activation status of signalling
components to be an indicator for behavioral nocicep-
tive phenotypes. If and how signalling cascades can be
activated therefore adds a novel layer of complexity to
nociceptor functionality, which so far is mostly defined
just by ion channel expression. In addition, we demon-
strated that EGF show different functionality than NGF
or GDNF and that EGF is a new potential analgesic
modulator in the process of pain sensitization, a result
of importance not least in the light of the increased use
EGFR blockers for therapeutic cancer treatment.
Additional material
Additional file 1: Supplementary figure 1, Automatic control of
exposure time does not influence normalized signal intensity. The
DRG-culture was imaged with 0.96s six times until the fluorescence
signal was not decreasing anymore. Then the culture was imaged with
different usually used exposure times (between 0.24s and 0.96s) in a
different sequence. The mean intensities + standard deviations of 10
single cells, identified by their position on the slide, were compared to
observe any exposure time dependent intensity differences. There was
no significant difference of signal intensities in dependence of different
exposure times. Intensity values: 0.96 s: 0.384 ± 0.118; 0.48 s: 0.386 ±
0.118; 0.24 s: 0.396 ± 0.120; 0.48 s: 0.385 ± 0.120; 0.96 s: 0.378 ± 0.118;
0.24 s: 0.391 ± 0.117.
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